Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Browne

Showing results (351-360 of 364) with videos related to

Pageof 37
Sort By:
Immunity, Inflammation and Disease|May 31, 2022
Synbiotic containing extensively hydrolyzed formula improves gastrointestinal and atopic symptom severity, growth, caregiver quality of life, and hospital-related healthcare use in infants with cow's milk allergyGary P Hubbard, Kiranjit Atwal, Lynne Graham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2025
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH TrialIseult M Browne, Javier Pascual, Rosalind J Cutts, et al.
Angewandte Chemie (International Ed. in English)|April 20, 2026
A Synergistic Inhibitor Development Strategy Against Human UDP-Galactose-4-EpimeraseWilliam M Browne, Jonathan Pettinger, Teresa Weckwerth, et al.
Journal of Medicinal Chemistry|June 26, 2024
Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell LymphomaMatthew M Weiss, Xiaozhang Zheng, Nan Ji, et al.
Cell Chemical Biology|March 5, 2020
Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent InhibitorsSindhu Carmen Sivakumaren, Hyeseok Shim, Tinghu Zhang, et al.
Journal of Medicinal Chemistry|August 16, 2024
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune DiseasesXiaozhang Zheng, Nan Ji, Veronica Campbell, et al.
Nature Communications|December 17, 2020
Neutralizing the pathological effects of extracellular histones with small polyanionsConnor H O' Meara, Lucy A Coupland, Farzaneh Kordbacheh, et al.
Breast Cancer Research and Treatment|October 4, 2024
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancerI M Browne, R A McLaughlin, C S Weadick, et al.
Nature Chemical Biology|June 3, 2020
Identification of a potent and selective covalent Pin1 inhibitorBenika J Pinch, Zainab M Doctor, Behnam Nabet, et al.
Biorxiv : the Preprint Server for Biology|March 27, 2026
Comparison of Four Assays That Measure Antibodies to Ebola Virus GlycoproteinIrina Maljkovic Berry, Safaa Ben Farhat, Viviane Callier, et al.
Pageof 37

Showing results (351-360 of 364) with videos related to

Sort By:
Pageof 37
Immunity, Inflammation and Disease|May 31, 2022
Synbiotic containing extensively hydrolyzed formula improves gastrointestinal and atopic symptom severity, growth, caregiver quality of life, and hospital-related healthcare use in infants with cow's milk allergyGary P Hubbard, Kiranjit Atwal, Lynne Graham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2025
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH TrialIseult M Browne, Javier Pascual, Rosalind J Cutts, et al.
Angewandte Chemie (International Ed. in English)|April 20, 2026
A Synergistic Inhibitor Development Strategy Against Human UDP-Galactose-4-EpimeraseWilliam M Browne, Jonathan Pettinger, Teresa Weckwerth, et al.
Journal of Medicinal Chemistry|June 26, 2024
Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell LymphomaMatthew M Weiss, Xiaozhang Zheng, Nan Ji, et al.
Cell Chemical Biology|March 5, 2020
Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent InhibitorsSindhu Carmen Sivakumaren, Hyeseok Shim, Tinghu Zhang, et al.
Journal of Medicinal Chemistry|August 16, 2024
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune DiseasesXiaozhang Zheng, Nan Ji, Veronica Campbell, et al.
Nature Communications|December 17, 2020
Neutralizing the pathological effects of extracellular histones with small polyanionsConnor H O' Meara, Lucy A Coupland, Farzaneh Kordbacheh, et al.
Breast Cancer Research and Treatment|October 4, 2024
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancerI M Browne, R A McLaughlin, C S Weadick, et al.
Nature Chemical Biology|June 3, 2020
Identification of a potent and selective covalent Pin1 inhibitorBenika J Pinch, Zainab M Doctor, Behnam Nabet, et al.
Biorxiv : the Preprint Server for Biology|March 27, 2026
Comparison of Four Assays That Measure Antibodies to Ebola Virus GlycoproteinIrina Maljkovic Berry, Safaa Ben Farhat, Viviane Callier, et al.
Pageof 37